Efficacy and safety of natalizumab in multiple sclerosis

[MSUK]

Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results

Abstract

BACKGROUND: Clinical trials established the efficacy and safety of natalizumab. Data are needed over longer periods of time and in the clinical practice setting..... Read More -http://www.ms-uk.org/tysabri

[HarryZ]

Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results

Abstract

BACKGROUND: Clinical trials established the efficacy and safety of natalizumab. Data are needed over longer periods of time and in the clinical practice setting..... Read More -http://www.ms-uk.org/tysabri

The stats reported don't seem to include the approx 39% of the participants from the initial numbers. Is this just poor reporting of the study or what happened to these patients?

[grandsons4]

Perhaps they hadn't yet reached the minimum two-year threshold reported on.

[HarryZ]

Perhaps they hadn't yet reached the minimum two-year threshold reported on.

Then they should not have been a part of the study's reporting numbers on efficacy. Something just doesn't seem right here.

[CureOrBust]

I think the missing numbers may be partially made up of those that came up as JCV positive, and hence advised to stop taking it, but not "technically" being diagnosed or suffer specific JCV symptoms.

[HarryZ]

I think the missing numbers may be partially made up of those that came up as JCV positive, and hence advised to stop taking it, but not "technically" being diagnosed or suffer specific JCV symptoms.

Hi Cure,

Do you think that if this was the case, those numbers should have been shown as affecting the efficacy numbers in a negative way? I think what happens in some of these studies is those patients who drop out for whatever reason are simply ignored in the overall stats.